ArticleStem cell research & therapy2025
Cryogenic microcarrier-assisted stem cell storage (Cryo-MASCS): a preservation method enabling scalable culture of human mesenchymal stem cells.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microcarrier (µC) suspension systems enable closed, high-density manufacturing of human mesenchymal stem cells (MSCs), but current workflows remain labor-intensive because they require post-thaw cryoprotectant removal and static culture steps to allow cell attachment. To address these bottlenecks, we developed a cryogenic microcarrier-assisted stem cell storage (Cryo-MASCS) workflow that integrates cell attachment, cryopreservation, and thawing directly on surface-engineered µCs. MSCs were pre-seeded onto µCs coated with stacked heparan sulfate-collagen bilayers, cryopreserved on-carrier in either conventional dimethyl sulfoxide (DMSO)-supplemented medium or a DMSO-free, serum-free (SF) minimally supplemented medium, and then thawed and returned directly to suspension culture without intermediate processing. We optimized cell seeding density to maximize recovery. Following thaw, MSCs on engineered µCs and cryopreserved in either DMSO-containing or DMSO-free media retained viability comparable to traditional suspension cultures in DMSO-containing medium, while remaining attached to the carrier surface. Surface-engineered µCs show increased MSC yield within seven days in SF medium, significantly outperforming commercial collagen-coated µCs. Moreover, MSCs recovered metabolic activity and retained robust suppression of lipopolysaccharide-induced M1 macrophage polarization after IFN-γ priming. These findings demonstrate that direct cryopreservation of MSCs on heparan sulfate-collagen-coated µCs is compatible with both DMSO-free and DMSO-supplemented conditions and supports streamlined, scalable culture of undifferentiated MSCs for translational applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.